Mark Leuchtenberger, MBA, joined the NeuroSense Board of Directors as Chairman in October 2021. He is currently Executive Chairman of Aleta Biotherapeutics and was formerly CEO of Brooklyn ImmunoTherapeutics and Chairman, President and CEO of IRX Therapeutics.
Mr. Leuchtenberger has over 25 years of experience as a senior executive in the biopharmaceutical industry where he has led companies through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits. Mr. Leuchtenberger was President and Chief Executive Officer and a member of the board of directors at Chiasma (NASDAQ: CHMA), Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.) and served as President and CEO of Targanta Therapeutics Corporation, and Therion Biologics Corporation.
Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Inc., where he led the late-stage development of Avonex and its commercialization in North America and internationally in 65 countries. He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors and is a cofounder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. Mr. Leuchtenberger received his MBA from the Yale School of Management and his BA from Wake Forest University.